UPMC Hillman Cancer Center

Decade-long persistence of CD19 CAR T cells in B cell lymphomas

Abstract Chimeric antigen receptor (CAR) T cell therapy induces durable remissions in lymphoid malignancies, yet the extent and biology of long-term CAR T cell persistence in B cell lymphoma remain unclear. Here we report the persistence and characteristics of 4-1BB-costimulated...

Early versus late JAK-STAT–IFN signaling distinguishes no rejection from subclinical to clinical TCMR after liver transplantation

Subclinical rejection after liver transplantation precludes immunosuppression withdrawal despite normal clinical function. To better understand the immunobiology of early subclinical rejection, we performed longitudinal, multimodal immune profiling and single-cell RNA sequencing...

A dependency map enhanced with next-generation 3D cancer models

Despite advances in precision oncology, effective personalized treatments are still lacking for most patients with cancer1. The Cancer Dependency Map (DepMap) accelerates this field by systematically identifying cancer vulnerabilities in diverse preclinical models. Data from over...

Nanocarrier-mediated targeting of chemotherapy-induced DPP4 enhances T cell infiltration and improves cancer immunochemotherapy

Cancer immunotherapy has transformed cancer treatment, yet its efficacy remains limited by a “cold” tumor immune microenvironment (TIME) characterized by poor T cell infiltration. Induction of immunogenic cell death (ICD) improves T cell infiltration by promoting the release of T...